Guizhou Yibai Pharmaceutical Co Ltd (600594.SS)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- China stocks rise on optimism over Beijing's reform ambition
- China, Hong Kong stocks cheer Beijing's commitment to reform
- BRIEF-Guizhou Yibai Pharma plans to buy back 200 mln yuan worth of shares
- BRIEF-Guizhou Yibai Pharmaceutical issues 2017 first tranche corporate bonds worth 500 mln yuan
- BRIEF-Guizhou Yibai Pharmaceutical sets coupon rate of 2017 1st tranche corporate bonds at 5.9 pct